Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT04617704
NCT04617704UnknownPhase 1

Exploratory Study to Evaluate Efficacy and Safety of GC012F Injection in Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

Shanghai Changzheng Hospital1 site in 1 country15 target enrollmentStarted: December 1, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Phase 1
Enrollment
15
Locations
1
Primary Endpoint
Incidence and severity of adverse events after GC012F injection
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is a single arm, open label, multi-center prospective study to explory the safety and efficacy of GC012F CAR-T cells in patient diagnosed with high-risk chromosomal abnormalities BCMA+ multiple myeloma(MM).

Detailed Description

The main aim of this study is to determin the safety and efficacy of GC012F in cytogenetic high-risk MM. GC012F is an autologus dual chimeric antigen receptor T-cell(CAR-T) therapy that targets B-cell maturation antigen(BCMA) and CD19. This study comprises of a screening phase(less than or equal to 28 days prior to apheresis) followed by apheresis(will occur upon enroiiment); Treatment Phase including autologus stem cell transplant on Day-1 followed by infusion of GC012F on Day0 and then post-infusion assessments from Day1 to Day 84; and a Post-treatment Phase(Day 85 and up to end of the study). Efficacy will be explored to assessed and safety will be closely monitored during the study.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Diagnosis of active MM as defined by any of following: a) serum M protein more than or equal to 10g/dL; b) urine M protein more than or equal to 200mg/24 h; c) involved serum free light chain more than or equal to 100mg/dL with abnormal serum kappa lambda ratio;
  • •Patients with clear BCMA expression(percent of BCMA positive plasma cells more than or equal to 20%) detected by flow cytometry;
  • •High-risk chromosomal abnormal defined as presence of del17p, and/or t(4;14) and/or t(14;16);
  • •Estimated life expectancy more than or equal to 3 months;
  • •Absolute neutrophil count more than or equal to 1*10^9/L;
  • •Platelet count more than or equal to 25*10^9/L;
  • •Absolute lymphocyte count more than or equal to 1*10^8/L;
  • •Liver, kidney and cardiopulmonary functions meet the following requirements: a) Total bilirubin less than or equal to 2*ULN(except for Gilbert Syndrome); ALT and AST less than or equal to 2.5*ULN, maintenance of kidney function not depend on dialysis; c)Corrected serum calcium less than or equal to 12.5 mg/dL or free ion calcium less than or equal to 6.5mg/dL(1.6mmol/L);
  • •Sufficient venous access for leukapheresis collection and no other contraindications to leukapheresis;
  • •Subjects and sexual partner with fertility are willing to use effective and reliable method of contraception for at least 1 year after CAR-T infusion;
  • •subjects must have signed writtern informed consent.

Exclusion Criteria

  • •Accompanied by other unctrolled maligancies. Two exceptions to this criteria: Recepted radical therapy carcinoma without activity within 3 years before screening; fully treated skin non-melanoma;
  • •Any situations not benefit for subjects to accept or tolerated to planned therapy or understand informed consent; or any situation in which investigators believe that participation in this study is not in the subject's best intreat(eg., harm to health), or any situation that may prevent, limit or confuse the assessment;
  • •Convulsion or stoke within past 6 months;
  • •Any instability or systemic disease within 6 months prior to screening, including but not limited to congestive heart failure(New York heart association classification ≥ III)， unstable angina, cerebrovascular accident, or transient cerebral ischemic, myocardial infarction, LEVF<50%(assessed by an echocardiogram or multi-door circuit scan);
  • •Patients have central nervous system(CNS) metastases or CNS involvement(including cranial neuropathies or mass lesions and leptomeningeal disease);
  • •Subjects with positive HBsAg or HBcAb positive and peripheal blood HBV-DNA titer is higher than the lower limit of detection of the research institution; HCV antibody positive; HIV antibody positive; syphilis primary screening antibody positive;
  • •Presence or suspicious of fungi, bacteria, viruses or other infections that are uncontrollable or requiring intravenous treatment;
  • •Activity of autoimmune disease (such as crohn's disease, rheumatoid arthritis, systemic lupus erythematosus), orhistory of autoimmune disease within the last 3 years;
  • •Clinical evidence of dementia or changes of mental state;
  • •Exist of pulmonary fibrosis;
  • •Allergy subjects or history of severe hypersensitivity;
  • •Oxgen inhalation requirement to maintain adequate oxygen saturation;
  • •Surgery (except for local anesthesia surgery) plan 2 weeks before apheresis, during or 2 weeks after CAR-T infusion;
  • •Patients who are accounted to be not appropriate for this investigator.

Arms & Interventions

Experimental:GC012F treatment

Experimental

BCMA+ cytogenetic high-risk multiple myeloma patients be treated with a single dose of GC012F cells. Total dose of (1-5)*10^5/kg cells will be administered at Day 0

Intervention: GC012F injection (Biological)

Outcomes

Primary Outcomes

Incidence and severity of adverse events after GC012F injection

Time Frame: Minimum 2 years after GC012F infusion

Secondary Outcomes

  • Overall survivalof subjects after GC012F treatment(Minimum 2 years after GC012F infusion(Day0))
  • Duration of response of subjects after GC012F treatment(Minimum 2 years after GC012F infusion(Day0))
  • Progression free survival after GC012F treatment(Minimum 2 years after GC012F infusion(Day0))
  • Cytokines in serum after GC012F infusion(Minimum 24 weeks after GC012F infusion(Day0))
  • Subset of lymphocytes in blood after GC012F infusion(Minimum 2 years after GC012F infusion(Day0))
  • ORR(PR, VGPR, CR and sCR) of patients after GC012F treatment(Minimum 2 years after GC012F infusion(Day0))
  • Anti-GC012F antibodies in blood after GC012F infusion(Minimum 2 years after GC012F infusion(Day0))
  • Percentage of MRD negative patients after GC012F infusion(Minimum 2 years after GC012F infusion)
  • Cell counts of GC012F in blood and bone marrow(if available) after GC012F infusion(Minimum 2 years after GC012F infusion(Day0))
  • Copies of GC012F in blood and bone marrow(if available) after GC012F infusion(Minimum 2 years after GC012F infusion(Day0))

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Weijun Fu

Director of Hematology Department

Shanghai Changzheng Hospital

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Phase 1
BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple MyelomaMultiple Myeloma
NCT04236011Shanghai Changzheng Hospital15
Withdrawn
Phase 1
CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHLB-cell Lymphoma
NCT04877080920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Completed
Not Applicable
EndoRotor DEN (Direct Endoscopic Necrosectomy)TrialNecrotizing PancreatitisAcute PancreatitisAcute Pancreatic Necrosis
NCT03694210Interscope, Inc.30
Recruiting
Early Phase 1
Anti-CD19-CAR-T Cells in Subjects with Relapsed/Refractory B Cell MalignanciesB-Cell Malignancy
NCT06532630Shanghai First Song Biotechnology Co., LTD9
Completed
Not Applicable
LILRB4 STAR-T Cell Therapy for Monocytic LeukemiaAcute Myelogenous LeukemiaChronic Myelomonocytic Leukemia
NCT05739409Institute of Hematology & Blood Diseases Hospital, China1